AVIR · Insider Trading
Atea Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by AVIR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-23 | Bruno Lucidi | Director | M | +29,600 | — |
| 2026-06-23 | Jerome M. Adams | Director | M | +29,600 | — |
| 2026-06-23 | Howard Berman | Director | A | +64,400 deriv. | — |
| 2026-06-23 | Bruce Polsky | Director | M | +29,600 | — |
| 2026-06-23 | Arthur S Kirsch | Director | A | +64,400 deriv. | — |
| 2026-06-23 | Polly A. Murphy | Director | M | +29,600 | — |
| 2026-06-23 | Franklin M Berger | Director | M | +29,600 | — |
| 2026-06-23 | Barbara Gayle Duncan | Director | M | +29,600 | — |
| 2026-05-21 | Polly A. Murphy | Director | Buy | +6,100 | +$25.45K |
| 2026-05-20 | Polly A. Murphy | Director | Buy | +6,100 | +$25.45K |
| 2026-03-13 | Andrea Corcoran | See Remarks | M | +60,000 | +$74.40K |
| 2026-02-03 | Andrea Corcoran | See Remarks | MIXED | +38,762 | −$68.28K |
| 2026-02-03 | Wayne Foster | EVP, Chief Accounting Officer | MIXED | +29,201 | −$51.44K |
| 2026-02-03 | Jean-Pierre Sommadossi | President, CEO, and Chairman | MIXED | +466,890 | −$77.83K |
| 2026-02-03 | John Vavricka | Chief Commercial Officer | MIXED | +30,513 | −$49.06K |
| 2026-02-03 | Maria Arantxa Horga | Chief Medical Officer | MIXED | +35,210 | −$68.15K |
| 2026-02-03 | Janet MJ Hammond | Chief Development Officer | MIXED | +43,914 | −$59.94K |
| 2025-06-24 | Howard Berman | Director | A | +164,800 deriv. | — |
| 2025-06-24 | Jerome M. Adams | Director | M | +29,600 | — |
| 2025-06-24 | Franklin M Berger | Director | M | +29,600 | — |
| 2025-06-24 | Bruce Polsky | Director | M | +29,600 | — |
| 2025-06-24 | Bruno Lucidi | Director | M | +29,600 | — |
| 2025-06-24 | Polly A. Murphy | Director | M | +29,600 | — |
| 2025-06-24 | Barbara Gayle Duncan | Director | M | +29,600 | — |
| 2025-02-24 | Arthur S Kirsch | Director | A | +164,800 deriv. | — |
| 2025-02-04 | Janet MJ Hammond | Chief Development Officer | MIXED | +43,916 | −$43.25K |
| 2025-02-04 | Andrea Corcoran | See Remarks | MIXED | +38,765 | −$49.27K |
| 2025-02-04 | Jean-Pierre Sommadossi | President, CEO, and Chairman | MIXED | +184,383 | −$271.12K |
| 2025-02-04 | John Vavricka | Chief Commercial Officer | MIXED | +30,566 | −$35.24K |
| 2025-02-04 | Maria Arantxa Horga | Chief Medical Officer | MIXED | +35,212 | −$49.18K |
| 2025-02-04 | Wayne Foster | EVP, Chief Accounting Officer | MIXED | +29,271 | −$36.91K |
| 2025-01-17 | Franklin M Berger | Director | Buy | +25,000 | +$81.50K |
| 2025-01-17 | Franklin M Berger | Director | Buy | −25,000 | −$81.50K |
| 2024-12-12 | Franklin M Berger | Director | Sell | −359,606 | −$1.02M |
| 2024-09-19 | Jean-Pierre Sommadossi | President, CEO, and Chairman | Sell | −57,969 | −$234.16K |
| 2024-06-21 | Polly A. Murphy | Director | A | +70,800 deriv. | — |
| 2024-06-21 | Barbara Gayle Duncan | Director | A | +70,800 deriv. | — |
| 2024-06-21 | Bruce Polsky | Director | Sell | −17,544 | −$61.14K |
| 2024-06-21 | Bruno Lucidi | Director | A | +70,800 deriv. | — |
| 2024-06-21 | Franklin M Berger | Director | A | +70,800 deriv. | — |
| 2024-06-21 | Jerome M. Adams | Director | A | +70,800 deriv. | — |
| 2024-06-18 | Jerome M. Adams | Director | M | +33,150 | — |
| 2024-06-18 | Barbara Gayle Duncan | Director | M | +33,150 | — |
| 2024-06-18 | Polly A. Murphy | Director | M | +33,150 | — |
| 2024-06-18 | Bruno Lucidi | Director | M | +33,150 | — |
| 2024-06-18 | Bruce Polsky | Director | M | +33,150 | — |
| 2024-06-18 | Franklin M Berger | Director | M | +33,150 | — |
| 2024-06-07 | Jean-Pierre Sommadossi | President, CEO, and Chairman | Sell | −1,006 | −$4.02K |
| 2024-02-02 | Andrea Corcoran | See Remarks | MIXED | +28,524 | −$60.91K |
| 2024-02-02 | Janet MJ Hammond | Chief Development Officer | MIXED | +32,771 | −$53.91K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jean-Pierre Sommadossi | President, CEO, and Chairman | 6,439,948 | $33.04M |
| Andrea Corcoran | See Remarks | 823,576 | $4.22M |
| Franklin M Berger | Director | 536,097 | $2.75M |
| John Vavricka | Chief Commercial Officer | 176,672 | $906.33K |
| Bruno Lucidi | Director | 142,350 | $730.26K |
| Polly A. Murphy | Director | 133,040 | $682.50K |
| Janet MJ Hammond | Chief Development Officer | 127,665 | $654.92K |
| Bruce Polsky | Director | 124,806 | $640.25K |
| Maria Arantxa Horga | Chief Medical Officer | 112,159 | $575.38K |
| Barbara Gayle Duncan | Director | 92,350 | $473.76K |
| Jerome M. Adams | Director | 92,350 | $473.76K |
| Wayne Foster | EVP, Chief Accounting Officer | 79,329 | $406.96K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AVIR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.